166 related articles for article (PubMed ID: 25430999)
1. Bone metastases and skeletal-related events from neuroendocrine tumors.
Van Loon K; Zhang L; Keiser J; Carrasco C; Glass K; Ramirez MT; Bobiak S; Nakakura EK; Venook AP; Shah MH; Bergsland EK
Endocr Connect; 2015 Mar; 4(1):9-17. PubMed ID: 25430999
[TBL] [Abstract][Full Text] [Related]
2. The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer.
Delea T; Langer C; McKiernan J; Liss M; Edelsberg J; Brandman J; Sung J; Raut M; Oster G
Oncology; 2004; 67(5-6):390-6. PubMed ID: 15713995
[TBL] [Abstract][Full Text] [Related]
3. Examination of burden of skeletal-related events in patients naive to denosumab and intravenous bisphosphonate therapy in bone metastases from solid tumors population.
Bhowmik D; Song X; Intorcia M; Gray S; Shi N
Curr Med Res Opin; 2019 Mar; 35(3):513-523. PubMed ID: 30286662
[TBL] [Abstract][Full Text] [Related]
4. Bisphosphonates and other bone agents for breast cancer.
Wong MH; Stockler MR; Pavlakis N
Cochrane Database Syst Rev; 2012 Feb; (2):CD003474. PubMed ID: 22336790
[TBL] [Abstract][Full Text] [Related]
5. Bone metastases in well-to-moderately differentiated neuroendocrine tumors: a single institutional review from the Ohio State University Medical Center.
Kavecansky J; Wei L; Caronia L; Ramirez MT; Bloomston M; Shah MH
Pancreas; 2015 Mar; 44(2):198-203. PubMed ID: 25411805
[TBL] [Abstract][Full Text] [Related]
6. Bisphosphonates for breast cancer.
Pavlakis N; Schmidt R; Stockler M
Cochrane Database Syst Rev; 2005 Jul; (3):CD003474. PubMed ID: 16034900
[TBL] [Abstract][Full Text] [Related]
7. Survival in breast cancer patients with bone metastases and skeletal-related events: a population-based cohort study in Denmark (1999-2007).
Yong M; Jensen AÖ; Jacobsen JB; Nørgaard M; Fryzek JP; Sørensen HT
Breast Cancer Res Treat; 2011 Sep; 129(2):495-503. PubMed ID: 21461730
[TBL] [Abstract][Full Text] [Related]
8. Bone Metastases in Neuroendocrine Tumors: Molecular Pathogenesis and Implications in Clinical Practice.
Cives M; Pellè E; Rinzivillo M; Prosperi D; Tucci M; Silvestris F; Panzuto F
Neuroendocrinology; 2021; 111(3):207-216. PubMed ID: 32403104
[TBL] [Abstract][Full Text] [Related]
9. Incidence, Risk Factors, and Survival of Bone Metastases and Skeletal-Related Events in Melanoma Patients: A Systematic Review and Quality Assessment of 29 Studies.
Shimizu MR; van de Langerijt ON; Torres D; de Groot T; Groot OQ
J Bone Oncol; 2024 Jun; 46():100603. PubMed ID: 38765703
[TBL] [Abstract][Full Text] [Related]
10. Reviewing the Osteotropism in Neuroendocrine Tumors: The Role of Epithelial-Mesenchymal Transition.
Cives M; Rizzo F; Simone V; Bisceglia F; Stucci S; Seeber A; Spizzo G; Montrone T; Resta L; Silvestris F
Neuroendocrinology; 2016; 103(3-4):321-34. PubMed ID: 26227818
[TBL] [Abstract][Full Text] [Related]
11. Early identification and intervention matters: A comprehensive review of current evidence and recommendations for the monitoring of bone health in patients with cancer.
Brodowicz T; Hadji P; Niepel D; Diel I
Cancer Treat Rev; 2017 Dec; 61():23-34. PubMed ID: 29100167
[TBL] [Abstract][Full Text] [Related]
12. Bisphosphonates for breast cancer.
Pavlakis N; Stockler M
Cochrane Database Syst Rev; 2002; (1):CD003474. PubMed ID: 11869664
[TBL] [Abstract][Full Text] [Related]
13. [The treatment for cancer with bone metastases -whether to use zoledoronate or denosumab for bone metastases-].
Kohno N
Clin Calcium; 2014 Aug; 24(8):1229-36. PubMed ID: 25065876
[TBL] [Abstract][Full Text] [Related]
14. Symptoms Related to Moderate Skeletal-Related Events as Clues for the Diagnosis of Bone Metastasis.
Kitagawa Y; Ito T; Mizuno Y; Sudo Y; Kim Y; Tsunoda R; Takai S
J Nippon Med Sch; 2019; 86(3):159-164. PubMed ID: 31292327
[TBL] [Abstract][Full Text] [Related]
15. The economic burden associated with skeletal-related events in patients with bone metastases secondary to solid tumors in Belgium.
Body JJ; Chevalier P; Gunther O; Hechmati G; Lamotte M
J Med Econ; 2013; 16(4):539-46. PubMed ID: 23425250
[TBL] [Abstract][Full Text] [Related]
16. Bone Metastases and Skeletal-Related Events in Medullary Thyroid Carcinoma.
Xu JY; Murphy WA; Milton DR; Jimenez C; Rao SN; Habra MA; Waguespack SG; Dadu R; Gagel RF; Ying AK; Cabanillas ME; Weitzman SP; Busaidy NL; Sellin RV; Grubbs E; Sherman SI; Hu MI
J Clin Endocrinol Metab; 2016 Dec; 101(12):4871-4877. PubMed ID: 27662441
[TBL] [Abstract][Full Text] [Related]
17. Survival and prognostic factors analysis of 151 intestinal and pancreatic neuroendocrine tumors: a single center experience.
Foubert F; Salimon M; Dumars C; Regenet N; Girot P; Venara A; Senellart H; Heymann MF; Matysiak-Budnik T; Touchefeu Y
J Gastrointest Oncol; 2019 Feb; 10(1):103-111. PubMed ID: 30788165
[TBL] [Abstract][Full Text] [Related]
18. Cost of skeletal-related events in European patients with solid tumours and bone metastases: data from a prospective multinational observational study.
Hechmati G; Cure S; Gouépo A; Hoefeler H; Lorusso V; Lüftner D; Duran I; Garzon-Rodriguez C; Ashcroft J; Wei R; Ghelani P; Bahl A
J Med Econ; 2013; 16(5):691-700. PubMed ID: 23441975
[TBL] [Abstract][Full Text] [Related]
19. Risk Factors for Developing Skeletal-Related Events in Breast Cancer Patients With Bone Metastases Undergoing Treatment With Bone-Modifying Agents.
Tanaka R; Yonemori K; Hirakawa A; Kinoshita F; Takahashi N; Hashimoto J; Kodaira M; Yamamoto H; Yunokawa M; Shimizu C; Fujimoto M; Fujiwara Y; Tamura K
Oncologist; 2016 Apr; 21(4):508-13. PubMed ID: 26975863
[TBL] [Abstract][Full Text] [Related]
20. Cost of skeletal complications from bone metastases in six European countries.
Pereira J; Body JJ; Gunther O; Sleeboom H; Hechmati G; Maniadakis N; Terpos E; Acklin YP; Finek J; von Moos R
J Med Econ; 2016 Jun; 19(6):611-8. PubMed ID: 26849381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
